As top pharmaceutical companies look to tap into the wealth of health care data from things like wearables and genetic tests, Pfizer is looking to partner with a number of companies in a bid to get ahead of the competition, according to a STAT report.
“We don’t necessarily generate real-world data,” Pfizer’s Christopher Boone tells STAT. “We generate clinical trial data and evidence, but we don’t generate real-world evidence right now. So we have to rely on our partnerships in order to get access to that data and conduct analyses. So the arms race is to solidify what I like to refer to as the data supply chain.”
To read the full report on STAT, click here. (Paid subscription required)